Pfizer Inc said Monday that it was launching a pilot program for Covid-19 immunization in four US states to help refine the plan for the delivery and deployment of its candidate vaccine.
The US pharmacist said it had selected Rhode Island, Texas, New Mexico and Tennessee for the program because of their differences in overall size, diversity of populations and immunization infrastructure, as well as the need for states to reach the people in various urban and rural areas. settings.
“The four states included in this pilot program will not receive vaccine doses earlier than other states under this pilot, nor will they receive any differential consideration,” Pfizer said in a statement.
Last Monday, Pfizer released initial data on its vaccine developed with German partner BioNTech SE that showed it to be more than 90% effective.
Earlier Monday, rival Moderna Inc said its experimental vaccine was 94.5% effective in preventing Covid-19 according to interim data from a late-stage trial, raising hopes that vaccines against the disease are ready for use soon.
Both the Pfizer and Moderna vaccines use a new technology called synthetic messenger RNA to activate the immune system against the virus.
Experts have raised concerns about the distribution challenges associated with Pfizer’s vaccine due to its specialized storage requirements.
The US pharmacist said it had selected Rhode Island, Texas, New Mexico and Tennessee for the program because of their differences in overall size, diversity of populations and immunization infrastructure, as well as the need for states to reach the people in various urban and rural areas. settings.
“The four states included in this pilot program will not receive vaccine doses earlier than other states under this pilot, nor will they receive any differential consideration,” Pfizer said in a statement.
Last Monday, Pfizer released initial data on its vaccine developed with German partner BioNTech SE that showed it to be more than 90% effective.
Earlier Monday, rival Moderna Inc said its experimental vaccine was 94.5% effective in preventing Covid-19 according to interim data from a late-stage trial, raising hopes that vaccines against the disease are ready for use soon.
Both the Pfizer and Moderna vaccines use a new technology called synthetic messenger RNA to activate the immune system against the virus.
Experts have raised concerns about the distribution challenges associated with Pfizer’s vaccine due to its specialized storage requirements.
.
